Electroacupuncture Pretreatment Alleviates Cerebral Ischemia-Reperfusion Injury by Increasing GSK-3β Phosphorylation Level via Adenosine A1 Receptor. [PDF]
Geng W+10 more
europepmc +1 more source
Adenosine A1 Receptor-Mediated Synaptic Depression in the Developing Hippocampal Area CA2. [PDF]
Caruana DA, Dudek SM.
europepmc +1 more source
NanoBiT Complementation to Monitor Agonist-Induced Adenosine A1 Receptor Internalization. [PDF]
Soave M+4 more
europepmc +1 more source
Adenosine A1 receptor: A neuroprotective target in light induced retinal degeneration. [PDF]
Soliño M+7 more
europepmc +1 more source
Adenosine A1 Receptor Agonist 2-chloro-N6-cyclopentyladenosine and Hippocampal Excitability During Brain Development in Rats. [PDF]
Fabera P+6 more
europepmc +1 more source
Downregulation of adenosine and adenosine A1 receptor contributes to neuropathic pain in resiniferatoxin neuropathy. [PDF]
Kan HW+5 more
europepmc +1 more source
Adenosine A1 receptor antagonism prevents DSI in hippocampal CA1 pyramidal cells: PS077. [PDF]
Freire J, Rombo DM, Sebastião AM.
europepmc +1 more source
Synthesis of novel (benzimidazolyl)isoquinolinols and evaluation as adenosine A1 receptor tools. [PDF]
Singh S+8 more
europepmc +1 more source
The glycoprotein nature of A1 adenosine receptors [PDF]
A1 adenosine receptors from different tissues and species were photoaffinity labelled and then the carbohydrate content was examined by both enzymatic and chemical treatment. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the labelled membrane receptors shows that neuraminidase treatment alters the electrophoretic mobility of the receptor
Klotz, Karl-Norbert, Lohse, M. J.
openaire +3 more sources
Related searches:
Allosteric modulators for the A1 adenosine receptor
Expert Opinion on Therapeutic Patents, 2004The present invention provides compounds of formula (I) wherein R1, R2, R3, R4 and Q have a meaning as defined herein in the specification. The compounds of formula (I) are allosteric modulators of the A1 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A1 adenosine receptor.
BARALDI, Pier Giovanni+4 more
openaire +5 more sources